Significance of the Percentage of Gleason Pattern 4 at Prostate Biopsy in Predicting Adverse Pathology on Radical Prostatectomy: Application in Active Surveillance

Am J Clin Pathol. 2023 Jul 5;160(1):35-40. doi: 10.1093/ajcp/aqad005.

Abstract

Objectives: To determine the prognostic significance of the maximum allowable percentage of Gleason pattern 4 (GP4) at prostate biopsy compared with adverse pathology observed at radical prostatectomy (RP) to expand active surveillance eligibility among a cohort with intermediate risk of prostate cancer.

Methods: A retrospective study of patients with grade group (GG) 1 or 2 prostate cancer on prostate biopsy with subsequent RP was performed at our institution. A Fisher exact test was used to understand the relationship among GP4 subgroups (0%, ≤5%, 6%-10%, and 11%-49%) assigned at biopsy and adverse pathologic findings at RP. Additional analyses comparing the GP4 ≤5% cohort's prebiopsy prostate-specific antigen (PSA) level and GP4 length with adverse pathology at RP were also performed.

Results: No statistically significant difference in adverse pathology at RP was observed between the active surveillance-eligible control (GP4 0%) and the GP4 ≤5% subgroup. In total, 68.9% of the GP4 ≤5% cohort showed favorable pathologic outcomes. A separate analysis of the GP4 ≤5% subgroup revealed that neither prebiopsy serum PSA levels nor GP4 length showed statistical correlation with adverse pathology at RP.

Conclusions: Active surveillance may be a reasonable option for management of patients in the GP4 ≤5% group until long-term follow-up data become available.

Keywords: Active surveillance; Gleason grade; Gleason pattern 4; Gleason score; Prostate biopsy; Prostate cancer; Prostate-specific antigen; Radical prostatectomy.

MeSH terms

  • Biopsy
  • Humans
  • Male
  • Neoplasm Grading
  • Prostate* / pathology
  • Prostate* / surgery
  • Prostate-Specific Antigen
  • Prostatectomy
  • Prostatic Neoplasms* / pathology
  • Retrospective Studies
  • Watchful Waiting

Substances

  • Prostate-Specific Antigen
  • GP 4